Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 11,176 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Paraplegia, Spinal Cord Injuries, Shoulder Pain, Tendinopathy
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • Galveston, Texas

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: MEDI6570, Placebo, Part B Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Anniston, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Medication Adherence
Interventions: Survey; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Davis, California • Indianapolis, Indiana • Minneapolis, Minnesota + 6 more

Conditions: Solid Tumors, Lymphoma
Interventions: ASTX660; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more

Conditions: Appendicitis, Child, Contrast Media
Interventions: CT Scan using IV contrast alone; Other
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 18 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Knee Disease, Knee Infection
Interventions: [F-18]MHF; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Central Serous Chorioretinopathy
Interventions: Mifepristone, Placebo; Drug
Lead sponsor: Roger Goldberg, M.D., MBA; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Walnut Creek, California • Boston, Massachusetts

Conditions: CML
Interventions: Imatinib Mesylate, IkT-001Pro; Drug
Lead sponsor: Inhibikase Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertension, Pulmonary
Interventions: Tadalafil, Placebo, ERA as specific PAH treatment; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 7
States / cities: Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more

Conditions: Frailty, Ventral Hernia
Interventions: Prehabilitation, Standard of Care (SOC); Behavioral · Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: TDF/FTC; Drug
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Temsirolimus, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-small Cell Lung Cancer
Interventions: Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Tucson, Arizona • Tampa, Florida • Royal Oak, Michigan

Conditions: Lung Diseases
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 35 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Multiple Sclerosis
Interventions: RO7121932 IV, RO7121932 SC; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Stanford, California • New Haven, Connecticut

Conditions: HCV Infection
Interventions: GS-9450, GS-9450 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: West Virginia University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Psoriasis
Interventions: Deucravacitinib, Systemic psoriasis medications, No systemic medications; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Lawrenceville, New Jersey

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 2,607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Plasma Cell Myeloma
Interventions: isatuximab SAR650984, lenalidomide, dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 5
States / cities: San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Entospletinib, Vincristine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Hattiesburg, Mississippi • Charleston, South Carolina

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT; Drug
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumors
Interventions: MEDI4736; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 47
States / cities: Scottsdale, Arizona • Burbank, California • Gilroy, California + 41 more

Search by objective public record fields.

Natural History of Shoulder Pathology in Manual Wheelchair Users

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

Antibiotic Adherence Practices in Dermatologic Surgery

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

CT Scan Using IV Contrast Alone for Pediatric Appendicitis

F18-MHF: Implants-Associated Infection Detection

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Ventral Hernia Repair

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Temsirolimus and Radiation for Non-Small Cell Lung Cancer

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

American Lung Association (ALA) Lung Health Cohort

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Prospective Study of Lymphoproliferative Diseases

A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

A Phase 1/2 Study to Evaluate MEDI4736